PRIME MEDICINE ($PRME) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$0.28 per share, missing estimates of -$0.26 by $0.02. The company also reported revenue of $860,000, missing estimates of $1,086,738 by $-226,738.
You can see Quiver Quantitative's $PRME stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PRIME MEDICINE Hedge Fund Activity
We have seen 109 institutional investors add shares of PRIME MEDICINE stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 8,122,781 shares (-88.1%) from their portfolio in Q4 2025, for an estimated $28,186,050
- STATE STREET CORP added 3,798,884 shares (+293.0%) to their portfolio in Q4 2025, for an estimated $13,182,127
- FARALLON CAPITAL MANAGEMENT LLC removed 3,509,157 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $12,176,774
- BALYASNY ASSET MANAGEMENT L.P. added 3,076,489 shares (+6426.4%) to their portfolio in Q4 2025, for an estimated $10,675,416
- RA CAPITAL MANAGEMENT, L.P. removed 3,000,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $10,410,000
- BLACKROCK, INC. added 2,617,984 shares (+46.3%) to their portfolio in Q4 2025, for an estimated $9,084,404
- VANGUARD GROUP INC added 1,546,007 shares (+31.4%) to their portfolio in Q4 2025, for an estimated $5,364,644
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
PRIME MEDICINE Analyst Ratings
Wall Street analysts have issued reports on $PRME in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for PRIME MEDICINE, check out Quiver Quantitative's $PRME forecast page.
PRIME MEDICINE Price Targets
Multiple analysts have issued price targets for $PRME recently. We have seen 4 analysts offer price targets for $PRME in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Kostas Biliouris from Oppenheimer set a target price of $11.0 on 03/12/2026
- An analyst from LifeSci Capital set a target price of $6.0 on 12/23/2025
- Samantha Semenkow from Citigroup set a target price of $4.25 on 11/11/2025
- Geulah Livshits from Chardan Capital set a target price of $9.0 on 11/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
